Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation

JAMA. 2004 Nov 3;292(17):2150-1. doi: 10.1001/jama.292.17.2150.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials, Phase I as Topic* / standards
  • Humans
  • Neoplasms / drug therapy*
  • Risk
  • Treatment Outcome

Substances

  • Antineoplastic Agents